ResultsIQ

ResultsIQ › Latest results › Privi Speciality Chemicals Limited

Privi Speciality Chemicals Limited Q2 FY26 earnings call summary

NSE: PRIVISCL · BSE: 530117

Earnings call of 7 Nov 2025, summarised by AI from the filing.

Privi Speciality Chemicals reported Q2 FY26 total income of ₹678.82 cr (up 26% YoY) and EBITDA of ₹182.14 cr (up 59% YoY), with EBITDA margin guidance of 24-26%.

Key takeaways

  1. Growth driver Volume growth of 17% and new product contributions drove revenue; China plus One shift benefits Privi.
  2. Risk Imported camphor dumping from China; anti-dumping duty steps initiated.

Original filing on BSE

Privi Speciality Chemicals Limited Q1 FY27 results

As filed: Revenue ₹666 cr (+19% year on year), EBITDA ₹152 cr (+15% year on year), PAT ₹82.8 cr (+43% year on year), EBITDA margin 22.9% (−76 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹722 cr (+18% year on year), EBITDA ₹180 cr (+36% year on year), PAT ₹94.1 cr (+47% year on year), EBITDA margin 25.0% (+332 bps). Score 47 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 332 bps year on year. Revenue rose ₹108 cr on a year ago, against ₹130 cr the year before. Share price after the results: −10.2% in 30 days (Nifty 500: −3.8%).
  • Q3 FY26: Revenue ₹605 cr (+23% year on year), EBITDA ₹151 cr (+34% year on year), PAT ₹74.9 cr (+70% year on year), EBITDA margin 25.0% (+202 bps). Score 68 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 202 bps year on year. Revenue fell 11% from last quarter. Revenue rose ₹114 cr on a year ago, more than the ₹87.0 cr it added the year before. Share price after the results: +5.3% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹679 cr (+27% year on year), EBITDA ₹182 cr (+64% year on year), PAT ₹90.0 cr (+100% year on year), EBITDA margin 26.8% (+598 bps). Score 82 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 598 bps year on year. Revenue rose ₹146 cr on a year ago, more than the ₹78.0 cr it added the year before. Share price after the results: +7.3% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹559 cr (+20% year on year), EBITDA ₹132 cr (+40% year on year), PAT ₹58.0 cr (+87% year on year), EBITDA margin 23.6% (+335 bps). Score 65 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 335 bps year on year. Revenue fell 9% from last quarter. Revenue rose ₹95.0 cr on a year ago, more than the ₹55.0 cr it added the year before. Share price after the results: −13.4% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹614 cr (+27% year on year), EBITDA ₹133 cr (+46% year on year), PAT ₹64.0 cr (+100% year on year), EBITDA margin 21.7% (+286 bps). Score 74 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 286 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +13.4% in 30 days (Nifty 500: +3.8%).
  • Q3 FY25: Revenue ₹491 cr (+22% year on year), EBITDA ₹113 cr (+27% year on year), PAT ₹44.0 cr (+52% year on year), EBITDA margin 23.0% (+98 bps). Score 65 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was below it. EBITDA margin rose 98 bps year on year. Revenue fell 8% from last quarter.
  • Q2 FY25: Revenue ₹533 cr (+17% year on year), EBITDA ₹111 cr (+25% year on year), PAT ₹45.0 cr (+50% year on year), EBITDA margin 20.8% (+127 bps). Score 73 of 100, Above trend. EBITDA margin rose 127 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Privi Speciality Chemicals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.